March 3, 2026Open Access

Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis

Key Points

Development of venous thromboembolism (VTE) risk is not accurately predicted by the Khorana Risk Score (KRS).
Clinical characteristics identified include multiple risk factors associated with VTE in both non-small cell and small cell lung cancer.

Structured PICO

Does the Khorana Risk Score accurately predict the risk of venous thromboembolism in patients with NSCLC and SCLC?

Population

Patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)

Intervention

Khorana Risk Score (KRS) assessment and clinical characteristics evaluation

Outcome

Incidence of venous thromboembolism (VTE)hard clinical

The Khorana Risk Score is insufficient on its own for predicting VTE in lung cancer patients, highlighting the need for updated risk stratification tools that incorporate additional clinical parameters.

Abstract

This study highlights the limitations of the KRS in predicting risk of development of VTE in patients with NSCLC and SCLC and identifies multiple clinical parameters associated with increased risk of VTE. Development of further risk stratification tools incorporating these clinical factors in addition to those in the KRS should be considered.

Bookmark

View Full Paper